Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 552,023
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Phone: 1-800-474-2737
HScottMatusow
HScottMatusow Oct. 25 at 12:05 AM
It's actually kinda funny reading X and Stocktwit posts from bears on $QURE. If you going to attempt a bear case, stop using data from 2 years ago, use current data, and stop calling Gene Therapy "a drug." Thank you for playing! $XBI $IBB $IWM $SPY
0 · Reply
JFais
JFais Oct. 24 at 8:14 PM
Lot of names out there that friends are pitching me= heads win big/tails loss is limited (opportunity cost as the main risk) Glad to see that vs chasing binaries, but I am biased as the former = my type of setup $XBI $IBB
0 · Reply
Arthur86
Arthur86 Oct. 24 at 3:52 PM
0 · Reply
SwingPlayers
SwingPlayers Oct. 24 at 3:51 PM
Hmmm $NEUP dropped from $20+ to $5’s and then an insider buys 639,110 shares at $5.14 Guess why he did that? Because it still has a partnership with Merck for the MK-1167 drug in phase 2 trial in Alzheimer’s disease with $450M milestone payments. $LABU $IBB
1 · Reply
ajbski
ajbski Oct. 24 at 1:44 PM
$NVAX Cantor Fitzgerald initiates coverage of Novavax with an Overweight rating and $18 Price Target. Oct. 24, 2025. 6:50 AM #Biotech #MatrixM #Nuvaxovid $IBB $XBI https://www.tipranks.com/news/the-fly/novavax-initiated-with-an-overweight-at-cantor-fitzgerald-thefly
0 · Reply
ajbski
ajbski Oct. 23 at 3:22 PM
$NVAX HC Wainwright & Co. Raises Price Target to $11, Maintains Buy Rating | #Biotech #Novavax $IBB $XBI GuruFocus News 10/23/2025 09:34 https://www.gurufocus.com/news/3157581/nvax-hc-wainwright-co-raises-price-target-to-11-maintains-buy-rating-nvax-stock-news
0 · Reply
thinkandpick
thinkandpick Oct. 23 at 8:01 AM
$PGNY $XLV $IBB $XBI $LABU Healthcare sector. Dirt-cheap Progyny (PGNY) with the fortress balance sheet announces another growth initiative effective January 2026, so there is no question that 2026 revenue will be higher than 2025 revenue: https://www.globenewswire.com/news-release/2025/10/22/3171210/0/en/Progyny-Expands-Global-Benefits-to-Include-Pregnancy-Postpartum-and-Menopause.html
0 · Reply
Its_Never_Too_Late
Its_Never_Too_Late Oct. 22 at 2:09 PM
1 · Reply
ajbski
ajbski Oct. 22 at 7:57 AM
$NVAX Yuge! “Detection of Anti-SARS-CoV-2 Mucosal Immunoglobulin A in Clinical Saliva Samples After a Dose of Novavax COVID-19 Vaccine” First published: 21 October 2025 Journal of Medical Virology, Volume 97, Issue 10 e70645 $NVAX #Biotech $XBI $IBB http://onlinelibrary.wiley.com/doi/10.1002/jm… https://x.com/sandcastle_kat/status/1980899413573914914?s=46
0 · Reply
JFais
JFais Oct. 21 at 8:59 PM
Like these "calls for prudence" after a big year (vs overleveraged accounts YOLOing binaries) Expect this to be a multi-year upswing for biotech and want to see everyone do well $XBI $IBB But equally important to avoid giving gains back to the market
0 · Reply
Latest News on IBB
Trade Tracker: Jason Snipe buys the IBB

Oct 17, 2025, 1:30 PM EDT - 7 days ago

Trade Tracker: Jason Snipe buys the IBB


Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI

Jul 6, 2025, 11:12 AM EDT - 3 months ago

Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI

XBI


Fast Money: WTI, IBB, UBER, CAT

Jun 13, 2025, 6:20 PM EDT - 4 months ago

Fast Money: WTI, IBB, UBER, CAT

UBER CAT


IBB: Now Is The Time To Be Contrarian

May 29, 2025, 10:59 AM EDT - 5 months ago

IBB: Now Is The Time To Be Contrarian


New vaccine chief rocks pharmaceutical stocks

May 7, 2025, 11:13 AM EDT - 6 months ago

New vaccine chief rocks pharmaceutical stocks

BNTX MRNA NVAX PFE GSK SRPT XBI


Sell into strength in pharma, says Mizuho's Jared Holz

Apr 11, 2025, 7:17 PM EDT - 7 months ago

Sell into strength in pharma, says Mizuho's Jared Holz

XBI


Invest In A New Biotech Bull Market With XBI And IBB

Mar 2, 2025, 8:33 AM EST - 8 months ago

Invest In A New Biotech Bull Market With XBI And IBB

XBI


iShares Biotechnology ETF: Playing Defense

Dec 10, 2024, 1:33 PM EST - 11 months ago

iShares Biotechnology ETF: Playing Defense


Health care stocks jump on Trump's nominee for FDA head

Nov 25, 2024, 6:22 PM EST - 11 months ago

Health care stocks jump on Trump's nominee for FDA head

HIMS LFMD MRNA PFE


Final Trade: Euro, IBB, SMH, NEM

Nov 20, 2024, 6:21 PM EST - 1 year ago

Final Trade: Euro, IBB, SMH, NEM

SMH NEM


Analyst is 'extremely bullish' on biopharma

Jul 30, 2024, 3:25 PM EDT - 1 year ago

Analyst is 'extremely bullish' on biopharma

MRK PFE


Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

XBI


For Biotech Stocks To Move Higher, This Must Move Lower

May 13, 2024, 9:00 AM EDT - 1 year ago

For Biotech Stocks To Move Higher, This Must Move Lower

XBI


Biotech's Next Gold Rush: Weight-Loss Drugs

Apr 2, 2024, 4:56 PM EDT - 1 year ago

Biotech's Next Gold Rush: Weight-Loss Drugs

LLY NVO


Catch The Medical Breakthroughs With The IBB ETF

Mar 28, 2024, 2:01 AM EDT - 1 year ago

Catch The Medical Breakthroughs With The IBB ETF


IBB: Let It Rest

Mar 26, 2024, 4:46 AM EDT - 1 year ago

IBB: Let It Rest


Why Biotech Stocks May Be Ready For A Recovery

Mar 9, 2024, 3:59 AM EST - 1 year ago

Why Biotech Stocks May Be Ready For A Recovery

BBH XLV


Navigating the big run in biotech

Feb 15, 2024, 1:44 PM EST - 1 year ago

Navigating the big run in biotech

XBI


HScottMatusow
HScottMatusow Oct. 25 at 12:05 AM
It's actually kinda funny reading X and Stocktwit posts from bears on $QURE. If you going to attempt a bear case, stop using data from 2 years ago, use current data, and stop calling Gene Therapy "a drug." Thank you for playing! $XBI $IBB $IWM $SPY
0 · Reply
JFais
JFais Oct. 24 at 8:14 PM
Lot of names out there that friends are pitching me= heads win big/tails loss is limited (opportunity cost as the main risk) Glad to see that vs chasing binaries, but I am biased as the former = my type of setup $XBI $IBB
0 · Reply
Arthur86
Arthur86 Oct. 24 at 3:52 PM
0 · Reply
SwingPlayers
SwingPlayers Oct. 24 at 3:51 PM
Hmmm $NEUP dropped from $20+ to $5’s and then an insider buys 639,110 shares at $5.14 Guess why he did that? Because it still has a partnership with Merck for the MK-1167 drug in phase 2 trial in Alzheimer’s disease with $450M milestone payments. $LABU $IBB
1 · Reply
ajbski
ajbski Oct. 24 at 1:44 PM
$NVAX Cantor Fitzgerald initiates coverage of Novavax with an Overweight rating and $18 Price Target. Oct. 24, 2025. 6:50 AM #Biotech #MatrixM #Nuvaxovid $IBB $XBI https://www.tipranks.com/news/the-fly/novavax-initiated-with-an-overweight-at-cantor-fitzgerald-thefly
0 · Reply
ajbski
ajbski Oct. 23 at 3:22 PM
$NVAX HC Wainwright & Co. Raises Price Target to $11, Maintains Buy Rating | #Biotech #Novavax $IBB $XBI GuruFocus News 10/23/2025 09:34 https://www.gurufocus.com/news/3157581/nvax-hc-wainwright-co-raises-price-target-to-11-maintains-buy-rating-nvax-stock-news
0 · Reply
thinkandpick
thinkandpick Oct. 23 at 8:01 AM
$PGNY $XLV $IBB $XBI $LABU Healthcare sector. Dirt-cheap Progyny (PGNY) with the fortress balance sheet announces another growth initiative effective January 2026, so there is no question that 2026 revenue will be higher than 2025 revenue: https://www.globenewswire.com/news-release/2025/10/22/3171210/0/en/Progyny-Expands-Global-Benefits-to-Include-Pregnancy-Postpartum-and-Menopause.html
0 · Reply
Its_Never_Too_Late
Its_Never_Too_Late Oct. 22 at 2:09 PM
1 · Reply
ajbski
ajbski Oct. 22 at 7:57 AM
$NVAX Yuge! “Detection of Anti-SARS-CoV-2 Mucosal Immunoglobulin A in Clinical Saliva Samples After a Dose of Novavax COVID-19 Vaccine” First published: 21 October 2025 Journal of Medical Virology, Volume 97, Issue 10 e70645 $NVAX #Biotech $XBI $IBB http://onlinelibrary.wiley.com/doi/10.1002/jm… https://x.com/sandcastle_kat/status/1980899413573914914?s=46
0 · Reply
JFais
JFais Oct. 21 at 8:59 PM
Like these "calls for prudence" after a big year (vs overleveraged accounts YOLOing binaries) Expect this to be a multi-year upswing for biotech and want to see everyone do well $XBI $IBB But equally important to avoid giving gains back to the market
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 7:40 PM
$FOLD continues to trade at lower multiples of projected sales versus 3 peers with like dollar forecasts & gross margin profiles. FOLD is currently defending its patent rights against a generic pharma hoping to sell a biosimilar. We suspect this could be the reason why FOLD does not trade at like multiples versus its peers $MIRM $TARS $KNSA Again by peers we mean those commercial-stage bios with similar revenue projections & patent lives. This is not investment advice. $IBB
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 5:34 PM
@outlawinvestor1 FYI $MRUS filed their 14D9 this morning that includes, among other things, the revenue forecast provided $GMAB as part of the broader financial projections. You were definitely right again. The MRUS forecasts, especially in the later years, are considerably higher than 3 analysts had projected. I prepared a simple comparison of the 2 showing you snapshots as well. We track these for all commercial-stage bios. It's our experience the projections are closer except for BPMC (BPMC's forecasts were much higher than analysts in the later years). I included an updated comparison of the various revenue multiples versus $PTGX as well. For those interested in clinical-stage bios (and commercial-stage for that matter), may I recommend you follow outlawinvestor1 Otherwise FYI only. This is not investment advice. $IBB $IBBQ
0 · Reply
sethmarcus
sethmarcus Oct. 21 at 3:43 PM
Me gusta, me gusta mucho! Health Care sector trying for its best closing price since March, and has absolutely no stocks within the sector trading with a bearish RSI (30 or <) $PFE $XLV $SPY $IBB $LLY
0 · Reply
JFais
JFais Oct. 21 at 1:34 PM
$XBI $IBB Liked the terminology (have heard in other phrasing/words)
0 · Reply
bOr_15Cave
bOr_15Cave Oct. 20 at 5:04 PM
$IBB biotech basket momentum. Entry 141.60, stop 138.90, PT 147.80. A push over 142.60 with 1.5 times 20D volume confirms. Good for staged adds while trailing risk.
0 · Reply
MessAndGetHorns
MessAndGetHorns Oct. 20 at 2:59 PM
$ESTA Where is the next resistance and new support? Love the price action. She has been on a tear and it's only just begun especially with the new tech they rolled out on their breast implants! $SPY $QQQ $IWM $IBB
2 · Reply
ZacksResearch
ZacksResearch Oct. 20 at 12:30 PM
Biotech’s back — and the rally looks real. 💥 $IBB, $ARKG, $SBIO, $BBC, and $BBP are soaring as Fed rate cut optimism, a wave of FDA approvals, fresh deals, and lower valuations spark major momentum across the sector. Find out what’s fueling biotech’s 2025 comeback 👉 https://www.zacks.com/stock/news/2772024/biotech-etfs-bounce-back-in-2025-heres-why?cid=sm-stocktwits-2-2772024-teaser-16718&ADID=SYND_STOCKTWITS_TWEET_2_2772024_TEASER_16718
0 · Reply
ZacksResearch
ZacksResearch Oct. 20 at 10:53 AM
Biotech boom: $IBB soars 30.2% in six months! 🚀 📊 Still undervalued with a forward P/E of 19.66X vs. the S&P 500 at 20.13X 💸 Fed's rate cuts offer cheaper funding, boosting growth potential 💊 Recent FDA approvals and strategic pharma deals add momentum Explore the full biotech rally story here 👉 https://www.zacks.com/stock/news/2772024/biotech-etfs-bounce-back-in-2025-heres-why?cid=sm-stocktwits-2-2772024-body-16720&ADID=SYND_STOCKTWITS_TWEET_2_2772024_BODY_16720
0 · Reply
QuantLake
QuantLake Oct. 19 at 8:21 PM
Gold Peaks, Crypto Slides Based on 3-month ROC rankings, the VanEck Gold Miners ETF $GDX rose to 54.0%, within the top decile of the past year. The iShares Biotechnology ETF $IBB and iShares Global Clean Energy ETF $ICLN followed near their yearly highs at 18.9% and 21.7%. While $GDX accelerated, the iShares Bitcoin Trust $IBIT dropped to -9.3%, near the 17th percentile. Infrastructure steadied, but real estate $VNQ stayed weak, barely above zero. Commodities and innovation hold momentum, while yield and property remain subdued.
0 · Reply
ajbski
ajbski Oct. 19 at 7:12 PM
$NVAX On October 13, 2025, SHAH CAPITAL MANAGEMENT added 300,000 shares of Novavax Inc at a trade price of $8.62 per share, marking a 2.61% increase in its position. VERY BULLISH SIGN FOR $NVAX #Biotech $IBB $XBI https://www.gurufocus.com/news/3149093/shah-capital-management-increases-stake-in-novavax-inc
0 · Reply
FairValTrading
FairValTrading Oct. 19 at 1:21 AM
0 · Reply
FairValTrading
FairValTrading Oct. 18 at 6:30 PM
might needs a push into $20S to stop the nonsense $16S ➡️ $13 🔜 16 rides. Co. well aligned with the #pharma #biotech insourcing and carries #transformational one if kind #IP. $XBI $IBB $ARK.X
0 · Reply